JANUX THERAPEUTICS INC (JANX) Stock Income Statement
NASDAQ:JANX - Nasdaq - US47103J1051 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.34M | 10.59M | 8.08M | 8.61M | 3.64M | |||
| Operating Expenses | 122.92M | 109.44M | 81.06M | 75.70M | 36.57M | |||
| Research and Development | 79.37M | 68.39M | 54.92M | 53.44M | 26.24M | |||
| Selling, General, and Administrative Expenses | 43.55M | 41.05M | 26.14M | 22.26M | 10.33M | |||
| Operating Income | -113.58M | -98.85M | -72.98M | -67.09M | -32.93M | |||
| Interest Income/Expense | 35.84M | 29.85M | 14.69M | 4.03M | 260.00K | |||
| Income Before Taxes | -77.74M | -68.99M | -58.29M | -63.06M | -32.67M | |||
| Net Income | -77.74M | -68.99M | -58.29M | -63.06M | -32.67M | |||
| EBITDA | -111.54M | -96.79M | -71.02M | -66.25M | -32.82M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.36 | -1.28 | -1.32 | -1.52 | -0.78 | |||
| Non GAAP EPS | -1.36 | -1.28 | -1.34 | -1.52 | N/A | |||
| Statistics | ||||||||
| Profit Margin | -832.71% | -651.62% | -721.18% | -732.40% | -897.53% | |||
| Operating Profit Margin | -1216.61% | -933.58% | -902.87% | -779.21% | -904.67% | |||
All data in USD